<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04067102</url>
  </required_header>
  <id_info>
    <org_study_id>TNBC-NEO</org_study_id>
    <nct_id>NCT04067102</nct_id>
  </id_info>
  <brief_title>Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC</brief_title>
  <official_title>Albumin Bound (Nab)-Paclitaxel Combined With Carboplatin Versus Paclitaxel Combined With Carboplatin Followed by Epirubicin and Cyclophosphamide as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Medical University Fourth Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hebei Medical University Fourth Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of P nab-paclitaxel combined with carboplatin versus&#xD;
      paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide in the&#xD;
      neoadjuvant treatment of triple negative breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No patients recruited&#xD;
  </why_stopped>
  <start_date type="Actual">May 10, 2019</start_date>
  <completion_date type="Anticipated">May 2026</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathologic complete response（pCR）</measure>
    <time_frame>6 months</time_frame>
    <description>pCR is defined as no histologic evidence of invasive tumor cells in the surgical breast specimen, axillary nodes, or sentinel node identified after neoadjuvant chemotherapy (ypT0/Tis ypN0)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival（DFS）</measure>
    <time_frame>5 years</time_frame>
    <description>Disease-free survival refers to the time from surgical resection of breast cancer to clinically confirmed local recurrence, distant metastasis, second primary tumor diagnosis, or patient death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival（OS）</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival is defined as the length of time from random assignment to death or to last contact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events（AEs）</measure>
    <time_frame>until 28 days after the last study drug administration</time_frame>
    <description>AEs are evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events v4.03.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Nab-paclitaxel Based Regimens</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel Based Regimens</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albumin bound (nab)-paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide</intervention_name>
    <description>Paclitaxel for injection (albumin binding)260mg/m2，I.v., d1；carboplatin AUC=5, I.v., d1； 21 days in one cycle, 4 cycles in total.Continue the protocol when evaluated as CR/PR/SD at the second cycle, Terminate the protocol paclitaxel (albumin binding) combined with carboplatin when evaluated as PD at the second cycle，and use the EC protocol in advance or decide the next treatment</description>
    <arm_group_label>Nab-paclitaxel Based Regimens</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide</intervention_name>
    <description>Paclitaxel 175mg/m2, I.v., d1； Carboplatin injection AUC 5, I.v., d1； 21 days in one cycle, 4 cycles in total.Continue the protocol when evaluated as CR/PR/SD at the second cycle, Terminate the protocol paclitaxel (albumin binding) combined with carboplatin when evaluated as PD at the second cycle，and use the EC protocol in advance or decide the next treatment protocol by the researcher</description>
    <arm_group_label>Paclitaxel Based Regimens</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female, aged ≥ 18 yrs and ≤70 yrs；&#xD;
&#xD;
          -  Histological confirmation of Unilateral primary invasive breast cancer, cT2-4NanyM0,&#xD;
             planning to receive neoadjuvant chemotherapy；&#xD;
&#xD;
          -  The expression of ER&lt;10%，PR &lt;10% and Her-2 negative by immunohistochemical, if HER2&#xD;
             expression ++, further FISH test confirmed no amplification of Her-2 gene；&#xD;
&#xD;
          -  ECOG performance status 0-1；&#xD;
&#xD;
          -  LVEF≥55%；&#xD;
&#xD;
          -  Bone marrow function: neutrophils ≥ 1.5×109/L, platelets ≥ 100×109/L, hemoglobin ≥ 90&#xD;
             g/L；&#xD;
&#xD;
          -  Liver and renal function：Serum creatinine ≤ 1.5x ULN；Aspartate aminotransferase (AST)&#xD;
             and alanine aminotransferase (ALT) ≤ 2.5x ULN；Total bilirubin ≤ 1.5x ULN or when&#xD;
             patients with Gilbert's syndrome ≤ 2.5x ULN；&#xD;
&#xD;
          -  The patient has good compliance with the planned treatment, understands the research&#xD;
             process of the study and signs a written informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cytotoxic chemotherapy, endocrine therapy or radiation therapy for any reason；&#xD;
&#xD;
          -  New York Heart Association (NYHA) score identifies patients with heart disease above&#xD;
             grade II (including grade II)；&#xD;
&#xD;
          -  Patients with severe systemic infections or other serious illnesses；&#xD;
&#xD;
          -  Patients known to be allergic or intolerant to chemotherapeutic drugs or their&#xD;
             excipients；&#xD;
&#xD;
          -  Combined with other malignant tumors or had malignant tumors other than breast cancer&#xD;
             in the past 5 years, except for cervical carcinoma in situ and non-melanoma skin&#xD;
             cancer that have been fully treated；&#xD;
&#xD;
          -  Women of childbearing age who are pregnant or lactating and who refuse to take&#xD;
             appropriate contraceptive measures during the trial；&#xD;
&#xD;
          -  Participated in other experimental studies within 30 days before the first dose of&#xD;
             study drug administration&#xD;
&#xD;
          -  Researchers judged patients who were unsuitable for this study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yunjiang Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hebei Medical University Fourth Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fourth Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 14, 2019</study_first_submitted>
  <study_first_submitted_qc>August 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2019</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hebei Medical University Fourth Hospital</investigator_affiliation>
    <investigator_full_name>Liu Yunjiang</investigator_full_name>
    <investigator_title>Professor, Director and Vice-president</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

